Stay updated on Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed information about a clinical trial for thymic carcinoma and the addition of new identifiers and collaborators, indicating a shift in focus or a revision of the trial's details.SummaryDifference52%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added, indicating a potential change in content or features effective from March 6, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 6, 2025, and version 2.14.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe webpage has updated its date references, removing several past dates and adding new ones for 2025, indicating a shift in the timeline of events or updates.SummaryDifference0.9%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.